As on Thursday, Akero Therapeutics Inc (NASDAQ: AKRO) started slowly as it slid -0.66% to $45.31, before settling in for the price of $45.61 at the close. Taking a more long-term approach, AKRO posted a 52-week range of $17.86-$58.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 0.00% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -5.28%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -12.72%. This publicly-traded company’s shares outstanding now amounts to $72.38 million, simultaneously with a float of $70.76 million. The organization now has a market capitalization sitting at $3.61 billion. At the time of writing, stock’s 50-day Moving Average stood at $42.57, while the 200-day Moving Average is $33.87.
Akero Therapeutics Inc (AKRO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Akero Therapeutics Inc’s current insider ownership accounts for 11.19%, in contrast to 87.63% institutional ownership. According to the most recent insider trade that took place on Apr 24 ’25, this organization’s Chief Scientific Officer sold 6,250 shares at the rate of 41.03, making the entire transaction reach 256,438 in total value, affecting insider ownership by 169,721. Preceding that transaction, on Apr 15 ’25, Company’s Chief Development Officer sold 9,073 for 37.91, making the whole transaction’s value amount to 343,962. This particular insider is now the holder of 95,034 in total.
Akero Therapeutics Inc (AKRO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.0 per share during the current fiscal year.
Akero Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -12.72% and is forecasted to reach -4.61 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -8.19% through the next 5 years, which can be compared against the -5.28% growth it accomplished over the previous five years trading on the market.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Let’s observe the current performance indicators for Akero Therapeutics Inc (AKRO). It’s Quick Ratio in the last reported quarter now stands at 19.38. The Stock has managed to achieve an average true range (ATR) of 2.45.
In the same vein, AKRO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.75, a figure that is expected to reach -0.96 in the next quarter, and analysts are predicting that it will be -4.61 at the market close of one year from today.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Through scrutinizing the latest numbers posted by the [Akero Therapeutics Inc, AKRO], it can be observed that its last 5-days Average volume of 1.29 million was lower the volume of 1.35 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 94.96% While, its Average True Range was 2.35.
Raw Stochastic average of Akero Therapeutics Inc (AKRO) in the period of the previous 100 days is set at 64.68%, which indicates a major fall in contrast to 94.81% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 30.50% that was lower than 121.99% volatility it exhibited in the past 100-days period.
